
Investigational Oral EGFR Inhibitor Shows Promising Efficacy in Pretreated NSCLC
An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable safety profile in patients with advanced non-small cell lung cancer (NSCLC) containing epidermal growth factor receptor (EGFR) exon …